News and Info

Welcome to the News and Info section of the ECOG-ACRIN Cancer Research Group website. The materials posted in this section are intended to keep constituents informed about the latest news and ongoing activities of the organization. This section contains announcements, news stories, press releases, and blogs.

We welcome inquiries from members of the press regarding the information posted on this website. To place a media inquiry, contact the Office of Communications.


Latest News

February 15, 2023

ASCO Living Guideline says ‘no’ to anti-VEGF-chemo combo in non-small cell lung cancer without driver alterations, based on data from the E5508 trial

February 10, 2023

The January/February 2023 News from ECOG-ACRIN blog is now available

February 10, 2023

ECOG-ACRIN announces the Remarkable Mentor to Women in Oncology Award (nominations are due March 9)

February 9, 2023

The application period is now open for Spring Meeting Attendance Awards for minority trainees

February 6, 2023

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer

February 1, 2023

Ongoing Trial: The INSPIRE research study is testing a new treatment approach for patients with advanced bladder cancer

January 30, 2023

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

January 24, 2023

Blinatumomab significantly improves overall survival in newly diagnosed B-ALL patients who are MRD-negative after initial treatment (study E1910)

January 5, 2023

The Winter 2023 advocacy blog Considering Clinical Trials is now available

December 20, 2022

The November/December 2022 News from ECOG-ACRIN blog is now available

December 19, 2022

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL

December 15, 2022

Study E1910 consolidates the role of blinatumomab in acute lymphoblastic leukemia (ALL)

December 14, 2022

Blinatumomab further improves survival among patients with B-ALL and a good prognosis (study E1910)

December 13, 2022

Immunotherapy Plus Consolidation Chemo Improves Survival in B Lineage ALL

December 13, 2022

HealthDay News informs the public of the 12-year TAILORx results

December 13, 2022

Blinatumomab regimen may lead to ‘diminishing use of transplant’ for B-ALL subgroup (study E1910)

December 13, 2022

Press Release: Practice-changing trial results for acute lymphoblastic leukemia (ALL)

December 11, 2022

Press Release: A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

December 6, 2022

Press Release: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes

October 28, 2022

Press Release: NCI Director Monica Bertagnolli delivers her first public speech at the ECOG-ACRIN Cancer Research Group meeting

 
ECOG-ACRIN Cancer Research Group